Celldex Therapeutics, Inc CLDX

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

CLDX hizo una agrupación de acciones (split inverso) de 1:15 el 11 de febrero de 2019: cada 15 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 23 sept

  The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte

  Four biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.

  

• GlobeNewswire Inc. 14 jun

  Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

  Celldex announced positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU), showing that up to 64% of patients remained angioedema-free seven months after treatment completion. The drug demonstrated rapid, significant, and durable improvements in angioedema symptoms, with potential to shift CSU treatment from symptom control to disease modification. Two Phase 3 trials enrolling 1,939 patients are ongoing with topline data expected in Q4 2026.

  

• GlobeNewswire Inc. 14 jun

  Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

  Celldex announced positive Phase 1 results for CDX-622, a novel bispecific antibody targeting soluble SCF and TSLP for inflammatory diseases. The drug demonstrated rapid, dose-dependent reductions in serum tryptase indicative of mast cell depletion and was well-tolerated at all dose levels. CDX-622 is now being studied in Phase 1b for mild to moderate asthma, with plans for additional proof-of-concept studies in allergic rhinitis and food allergy.